Literature DB >> 15249473

Narcotic and benzodiazepine use after withdrawal of life support: association with time to death?

Jeannie D Chan1, Patsy D Treece, Ruth A Engelberg, Lauren Crowley, Gordon D Rubenfeld, Kenneth P Steinberg, J Randall Curtis.   

Abstract

OBJECTIVE: To determine whether the dose of narcotics and benzodiazepines is associated with length of time from mechanical ventilation withdrawal to death in the setting of withdrawal of life-sustaining treatment in the ICU.
DESIGN: Retrospective chart review.
SETTING: University-affiliated, level I trauma center. PATIENTS: Consecutive critically ill patients who had mechanical ventilation withdrawn and subsequently died in the ICU during two study time periods.
RESULTS: There were 75 eligible patients with a mean age of 59 years. The primary ICU admission diagnoses included intracranial hemorrhage (37%), trauma (27%), acute respiratory failure (27%), and acute renal failure (20%). Patients died during a median of 35 min (range, 1 to 890 min) after ventilator withdrawal. On average, 16.2 mg/h opiates in morphine equivalents and 7.5 mg/h benzodiazepine in lorazepam equivalents were administered during the time period starting 1 h before ventilator withdrawal and ending at death. There was no statistically significant relationship between the average hourly narcotic and benzodiazepine use during the 1-h period prior to ventilator withdrawal until death, and the time from ventilator withdrawal to death. The restriction of medication assessment in the last 2 h of life showed an inverse association between the use of benzodiazepines and time to death. For every 1 mg/h increase in benzodiazepine use, time to death was increased by 13 min (p = 0.015). There was no relationship between narcotic dose and time to death during the last 2 h of life (p = 0.11).
CONCLUSIONS: We found no evidence that the use of narcotics or benzodiazepines to treat discomfort after the withdrawal of life support hastens death in critically ill patients at our center. Clinicians should strive to control patient symptoms in this setting and should document the rationale for escalating drug doses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15249473     DOI: 10.1378/chest.126.1.286

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  26 in total

1.  Killing the symptom without killing the patient.

Authors:  Romayne Gallagher
Journal:  Can Fam Physician       Date:  2010-06       Impact factor: 3.275

2.  Opioids and COPD.

Authors:  D M Van Renterghem
Journal:  Br J Clin Pharmacol       Date:  2016-01-17       Impact factor: 4.335

3.  [Finding the right words for medical decisions at life's end].

Authors:  Jürgen Wallner
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 4.  Predicting time to death after withdrawal of life-sustaining therapy.

Authors:  Laveena Munshi; Sonny Dhanani; Sam D Shemie; Laura Hornby; Genevieve Gore; Jason Shahin
Journal:  Intensive Care Med       Date:  2015-05-06       Impact factor: 17.440

5.  Incidence and Risk Model Development for Severe Tachypnea Following Terminal Extubation.

Authors:  Corey R Fehnel; Miguel Armengol de la Hoz; Leo A Celi; Margaret L Campbell; Khalid Hanafy; Ala Nozari; Douglas B White; Susan L Mitchell
Journal:  Chest       Date:  2020-04-28       Impact factor: 9.410

6.  ICU physicians' and nurses' perceptions of terminal extubation and terminal weaning: a self-questionnaire study.

Authors:  Alice Cottereau; René Robert; Amélie le Gouge; Mélanie Adda; Juliette Audibert; François Barbier; Patrick Bardou; Simon Bourcier; Alexandre Boyer; François Brenas; Emmanuel Canet; Daniel Da Silva; Vincent Das; Arnaud Desachy; Jérôme Devaquet; Nathalie Embriaco; Beatrice Eon; Marc Feissel; Diane Friedman; Frédérique Ganster; Maïté Garrouste-Orgeas; Guillaume Grillet; Olivier Guisset; Christophe Guitton; Rebecca Hamidfar-Roy; Anne-Claire Hyacinthe; Sebastien Jochmans; Fabien Lion; Mercé Jourdain; Alexandre Lautrette; Nicolas Lerolle; Olivier Lesieur; Philippe Mateu; Bruno Megarbane; Emmanuelle Mercier; Jonathan Messika; Paul Morin-Longuet; Bénédicte Philippon-Jouve; Jean-Pierre Quenot; Anne Renault; Xavier Repesse; Jean-Philippe Rigaud; Ségolène Robin; Antoine Roquilly; Amélie Seguin; Didier Thevenin; Patrice Tirot; Laetitia Contentin; Nancy Kentish-Barnes; Jean Reignier
Journal:  Intensive Care Med       Date:  2016-05-07       Impact factor: 17.440

7.  The Canadian guidelines for the withdrawal of life-sustaining treatment: the role of evidence.

Authors:  Mohamed Y Rady; Joseph L Verheijde
Journal:  Intensive Care Med       Date:  2016-05-25       Impact factor: 17.440

Review 8.  Symptom burden in heart failure: assessment, impact on outcomes, and management.

Authors:  Craig M Alpert; Michael A Smith; Scott L Hummel; Ellen K Hummel
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

9.  Predictors of time to death after terminal withdrawal of mechanical ventilation in the ICU.

Authors:  Colin R Cooke; David L Hotchkin; Ruth A Engelberg; Lewis Rubinson; J Randall Curtis
Journal:  Chest       Date:  2010-04-02       Impact factor: 9.410

10.  Withholding and withdrawal of life-sustaining treatment in a Lebanese intensive care unit: a prospective observational study.

Authors:  Alexandre Yazigi; Moussa Riachi; Georges Dabbar
Journal:  Intensive Care Med       Date:  2005-03-05       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.